DEPO-TESTADIOL (estradiol cypionate; testosterone cypionate) by Pfizer is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the treatment of: 1. First approved in 1980.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
DEPO-TESTADIOL is a fixed-dose combination injectable containing estradiol cypionate and testosterone cypionate, indicated for hormone replacement therapy in women. It works by binding to nuclear estrogen and androgen receptors to replace deficient endogenous hormones and modulate gonadotropin secretion. The product delivers sustained therapeutic levels through intramuscular injection with prolonged absorption over several weeks.
Product is approaching loss of exclusivity with low linked job availability, suggesting minimal team expansion and focus shifting toward LOE mitigation strategies.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on DEPO-TESTADIOL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moZero linked job openings signal a mature, stable product with minimal hiring; career growth on DEPO-TESTADIOL is limited to replacement and retention roles. This assignment is suitable for professionals seeking stability rather than rapid advancement or high visibility in dynamic launch environments.